BioSpace News Archive

Genetic analysis is the method of research and learning within the fields of molecular biology and genetics.

Transparency Market Research has published a new report titled, “Medical Aesthetic Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

Transparency Market Research has published a new report titled, ‘Pyrogen Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’. According to the report, the global Pyrogen Testing market was valued at US$ 742.0 Mn in 2018 and is projected to expand at a CAGR of 12.2% from 2019 to 2027.

Transparency Market Research has published a new report titled, “Urinary Incontinence Treatment Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global urinary incontinence treatment devices market was valued at US$ 2.21 Bn in 2018 and is projected to expand at a CAGR of 7.5% from 2019 to 2027.

Terra Biological LLC reports a new study, peer-reviewed and published by the Journal of Obstetrics and Gynecology Science, finds that daily intake of oxaloacetate significantly relieves Premenstrual Syndrome -related mood symptoms within the first menstrual cycle.

Approval makes Entyvio the only maintenance therapy approved across Europe with both intravenous and subcutaneous formulation options for adult patients with ulcerative colitis or Crohn’s disease

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has received a No Objection Letter from Health Canada to conduct a Phase II human trial for its lead drug LSALT peptide (Metablok) to prevent organ inflammation experienced by patients with COVID-19. The Phase II trial will be a multicenter, r

Net sales of $104.8 million, a decrease of 3.9% compared to prior year and 3.4% on a constant currency basis Cost management initiatives put in place to reduce cash burn Borrowed $100.0 million against the secured revolving credit facility to navigate uncertain macro-environment Closed the acquisition of the FITBONE intramedullary lengthening system assets

Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Bank of America Health Care Conference 2020 on Wednesday, May 13, 2020 at 1:40 p.m. ET. A live webcast of the presentation can be accessed on the investor page of Sag

TherapeuticsMD Announces Participation at the BofA Securities 2020 Health Care Conference